These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 3534713)

  • 21. Ceftriaxone against gram-negative and gram-positive bacteria: bactericidal and post-antibiotic effect.
    Ravizzola G; Bonfanti C; Savoldi E; Turano A
    Chemioterapia; 1985 Jun; 4(3):204-8. PubMed ID: 3875430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ceftazidime: in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics.
    Phillips I; Warren C; Shannon K; King A; Hanslo D
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():23-31. PubMed ID: 19802967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative in vitro activities of third-generation cephalosporins.
    Fass RJ
    Arch Intern Med; 1983 Sep; 143(9):1743-5. PubMed ID: 6615095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of beta-lactamase stability and antibacterial activity of beta-lactams in beta-lactamase-producing bacteria and respective transconjugants.
    Esposito S; Galante D; Barba D; Pennucci C; Limauro D
    Drugs Exp Clin Res; 1986; 12(4):329-33. PubMed ID: 3522155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New cephalosporins: in-vitro activity against gram-negative bacilli and suggestions for possible clinical use.
    Bakken JS; Hulsund M
    J Oslo City Hosp; 1984 May; 34(5):41-7. PubMed ID: 6086864
    [No Abstract]   [Full Text] [Related]  

  • 26. [Continuous surveillance of antimicrobial resistance among nosocomial gram-negative bacilli from intensive care units in China].
    Chen MJ; Wang H;
    Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):375-81. PubMed ID: 12820912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Susceptibility of 324 nonfermentative gram-negative rods to 6 cephalosporins and azthreonam.
    Appelbaum PC; Tamim J; Pankuch GA; Aber RC
    Chemotherapy; 1983; 29(5):337-44. PubMed ID: 6311492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Susceptibility of gentamicin sensitive and resistant gram negative bacilli to ceftazidime.
    Bremner DA
    Pathology; 1987 Jul; 19(3):274-6. PubMed ID: 3124067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of imipenem and six other beta-lactam antibiotics against aminoglycoside resistant gram-negative bacilli.
    Bujdáková H; Kallová J; Lausová A; Kettner M
    Microbios; 1995; 84(339):87-90. PubMed ID: 8628124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Moxalactam and cefotaxime--two new beta-lactam antibiotics compared with three well-known cephalosporins].
    Baumgärtner M; Dickgiesser N; Müller S; Wundt W
    Arzneimittelforschung; 1981; 31(10):1677-81. PubMed ID: 6274361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Susceptibility of bacteria to selected cephalosporins of the II and III generation].
    Nowakowska K; Szozda G; Pawluch D; Drejewicz H; Siwińska-Gołebiowska H
    Med Dosw Mikrobiol; 1993; 45(2):177-82. PubMed ID: 8309293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative in vitro activity of first, second and third generation cephalosporins.
    Forsgren A
    Acta Pathol Microbiol Scand B; 1981 Aug; 89(4):221-5. PubMed ID: 6274143
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Action of imipenem on Enterobacter cloacae].
    Donnio PY; Lebert P; Travert MF; Avril JL
    Pathol Biol (Paris); 1988 May; 36(5):456-9. PubMed ID: 3043343
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparative study of the in-vitro activity of cefepime and other cephalosporins.
    Lim VK; Halijah MY
    Malays J Pathol; 1993 Jun; 15(1):65-8. PubMed ID: 8277793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
    Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM
    J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An in-vitro comparison of new cephalosporins with special reference to Pseudomonas aeruginosa.
    van Klingeren B
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():97-105. PubMed ID: 19810171
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative in vitro activity of cefepime and four extended-spectrum beta-lactams on 1,251 aminoglycoside-resistant gram-negative hospital strains.
    Vanhoof R; Nulens E; Nyssen HJ; Hannecart-Pokorni E
    Chemotherapy; 1992; 38(4):225-31. PubMed ID: 1473361
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The in vitro activity, human pharmacology, and clinical effectiveness of new beta-lactam antibiotics.
    Neu HC
    Annu Rev Pharmacol Toxicol; 1982; 22():599-642. PubMed ID: 6282190
    [No Abstract]   [Full Text] [Related]  

  • 40. The cephalosporin antibiotic agents--III. Third-generation cephalosporins.
    Marsh TD
    Infect Control; 1985 Feb; 6(2):78-83. PubMed ID: 3882594
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.